keyword
MENU ▼
Read by QxMD icon Read
search

DAA

keyword
https://www.readbyqxmd.com/read/29146520/patterns-of-resistance-associated-substitutions-in-patients-with-chronic-hcv-infection-following-treatment-with-direct-acting-antivirals
#1
Julia Dietz, Simone Susser, Johannes Vermehren, Kai-Henrik Peiffer, Georgios Grammatikos, Annemarie Berger, Peter Ferenci, Maria Buti, Beat Müllhaupt, Bela Hunyady, Holger Hinrichsen, Stefan Mauss, Jörg Petersen, Peter Buggisch, Gisela Felten, Dietrich Hüppe, Gaby Knecht, Thomas Lutz, Eckart Schott, Christoph Berg, Ulrich Spengler, Thomas von Hahn, Thomas Berg, Stefan Zeuzem, Christoph Sarrazin
BACKGROUND & AIMS: Little is known about substitutions that mediate resistance of HCV to direct-acting antivirals (DAAs), due to the small number of patients with treatment failure in approval studies. It is important to identify resistance patterns to select effective salvage treatments. METHODS: We performed a comprehensive analysis for resistance-associated substitutions (RASs) in HCV genes (NS3, NS5A, NS5B) targeted by DAAs. We compared NS3, NS5A, and NS5B sequences from 626 patients in Europe with DAA failure with sequences from 2322 DAA-naïve patients, infected with HCV genotypes 1-4...
November 13, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29145802/effectiveness-of-current-and-future-regimens-for-treating-genotype-3-hepatitis-c-virus-infection-a-large-scale-systematic-review
#2
Hosnieh Fathi, Andrew Clark, Nathan R Hill, Geoffrey Dusheiko
BACKGROUND: Six distinct genetic variants (genotypes 1 - 6) of hepatitis C virus (HCV) exist globally. Certain genotypes are more prevalent in particular countries or regions than in others but, globally, genotype 3 (GT3) is the second most common. Patients infected with HCV GT1, 2, 4, 5 or 6 recover to a greater extent, as measured by sustained virological response (SVR), following treatment with regimens based on direct-acting antivirals (DAAs) than after treatment with older regimens based on pegylated interferon (Peg-IFN)...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29145306/dynamic-noninvasive-markers-predict-hepatocellular-carcinoma-in-chronic-hepatitis-c-patients-without-sustained-virological-response-after-interferon-based-therapy-prioritize-who-needs-urgent-direct-acting-antiviral-agents
#3
Chao-Min Huang, Tsung-Hui Hu, Kuo-Chin Chang, Po-Lin Tseng, Sheng-Nan Lu, Chien-Hung Chen, Jing-Houng Wang, Chuan-Mo Lee, Ming-Chao Tsai, Ming-Tsung Lin, Yi-Hao Yen, Chao-Hung Hung, Chung-Lung Cho, Cheng-Kun Wu
Some patients with hepatitis C virus (HCV) infections who fail to achieve sustained virological responses (SVRs) after interferon (IFN) therapy do not develop hepatocellular carcinoma (HCC). Risk stratification of these patients may help identify those who would benefit most from treatment with direct-acting antivirals (DAAs).A total of 552 HCV-infected patients with non-SVR status were enrolled. Laboratory data before and after IFN treatment were analyzed to determine the relationship of changes in serum markers with development of HCC during the 7-year study period...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29143681/economic-evaluation-of-hcv-testing-approaches-in-low-and-middle-income-countries
#4
REVIEW
Jake R Morgan, Maria Servidone, Philippa Easterbrook, Benjamin P Linas
BACKGROUND: Hepatitis C virus (HCV) infection represents a major public health burden with diverse epidemics worldwide, but at present, only a minority of infected persons have been tested and are aware of their diagnosis. The advent of highly effective direct acting antiviral (DAA) therapy, which is becoming available at increasingly lower costs in low and middle income countries (LMICs), represents a major opportunity to expand access to testing and treatment. However, there is uncertainty as to the optimal testing approaches and who to prioritize for testing...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29139181/direct-antiviral-treatment-of-chronic-hepatitis-c-in-heart-transplant-recipients
#5
Martina Vitrone, Roberto Andini, Irene Mattucci, Ciro Maiello, Luigi Atripaldi, Emanuele Durante-Mangoni, Rosa Zampino
Direct-acting antiviral agents (DAAs) are a safe and effective treatment for chronic hepatitis C (CHC). This may be particularly valuable for patients with severe comorbidities or baseline conditions, including non-liver solid organ transplant. We report cases of two heart transplant recipients with CHC treated with DAA (sofosbuvir and daclatasvir) achieving sustained virological response. Treatment was well tolerated and no relevant side effects were observed. The drug-drug interactions and graft function were carefully monitored...
November 15, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29136329/follow-up-of-sustained-virologic-responders-with-hepatitis-c-and-advanced-liver-disease-after-interferon-ribavirin-free-treatment
#6
Karin Kozbial, Stephan Moser, Ramona Al-Zoairy, Remy Schwarzer, Christian Datz, Rudolf Stauber, Hermann Laferl, Michael Strasser, Sandra Beinhardt, Albert Friedrich Stättermayer, Michael Gschwantler, Heinz Zoller, Andreas Maieron, Ivo Graziadei, Michael Trauner, Petra Steindl-Munda, Harald Hofer, Peter Ferenci
BACKGROUND: The introduction of direct-acting antivirals (DAA) has increased sustained virological response (SVR) rates in patients with advanced liver disease and chronic hepatitis C(CHC)infection. At present, data on clinical outcome and long-term durability of viral eradication after successful DAA therapy are scarce. AIM: To evaluate the long-term success of viral eradication in patients with advanced fibrosis or cirrhosis treated with DAAs. METHODS: Five hundred and fifty one patients with advanced fibrosis (n=158) or liver cirrhosis (CPS-A:317,CPS-B/C:76) and SVR after interferon and ribavirin-free DAA therapy treated between October 2013 and April 2016 were studied with a median follow-up of 65...
November 14, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29135574/interferon-free-therapy-for-treating-hcv-in-difficult-to-treat-hiv-coinfected-patients-as-implemented-in-routine-medical-practice
#7
Carlos Mínguez, Miguel García-Deltoro, Juan Flores, Maria-José Galindo, Marta Montero, Sergio Reus, Jorge Carmena, Mar Masiá, Concepción Amador, Enrique Ortega
BACKGROUND/AIMS: Data regarding the use of all-oral direct-acting antivirals (DAA) in HIV/HCV-coinfected patients with advanced liver fibrosis are required, because they are generally under-represented in clinical trials. This study sought to evaluate the use of these drugs in a cohort of coinfected patients, mostly with factors that have previously been recognised as predictors of treatment failure. METHODS: COINFECOVA-2 is an observational, multicenter study conducted in Eastern Spain...
November 10, 2017: AIDS
https://www.readbyqxmd.com/read/29135030/hepatitis-c-virus-clearance-in-older-adults
#8
Antonio Massimo Ippolito, Angelo Iacobellis, Michele Milella, Fabio Conti, Vincenzo Messina, Maria Rosa Valvano, Grazia Anna Niro, Filomena Morisco, Michele Barone, Antonio Patrizio Termite, Giuseppina Brancaccio, Angelo Andriulli
OBJECTIVES: To determine whether older adults with the hepatitis C virus (HCV) achieve a sustained viral response (SVR) after treatment with direct-acting antiviral therapy. PARTICIPANTS: Individuals aged 80 and older with chronic HCV infection (N = 253; n = 213 with cirrhosis, n = 40 with advanced fibrosis). MEASUREMENTS: We investigated the efficacy, safety, and global clinical effect of treatment with different combinations of direct antiviral agents (DAAs)...
November 14, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29134963/the-cochrane-review-conclusion-for-hepatitis-c-daa-therapies-is-wrong
#9
Paul Y Kwo, Mitchell L Shiffman, David E Bernstein
No abstract text is available yet for this article.
November 14, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29134328/correction-to-efficacy-and-safety-of-glecaprevir-pibrentasvir-in-hcv-infected-japanese-patients-with-prior-daa-experience-severe-renal-impairment-or-genotype-3-infection
#10
Hiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, Kenji Ikeda, Ken Sato, Hidenori Toyoda, Masanori Atsukawa, Akio Ido, Akinobu Takaki, Nobuyuki Enomoto, Koji Kato, Katia Alves, Margaret Burroughs, Rebecca Redman, David Pugatch, Tami J Pilot-Matias, Preethi Krishnan, Rajneet K Oberoi, Wangang Xie, Kazuaki Chayama
Unfortunately, in the original publication of this article, the copyright line was incorrectly published in PDF as "© The Author(s) 2017" instead of "©The Author(s) 2017 This article is an open access publication" and also the CC-BY description was not included. The description should be as follows.
November 13, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29134150/hcv-core-antigen-is-an-alternative-marker-to-hcv-rna-for-evaluating-active-hcv-infection-implications-for-improved-diagnostic-option-in-an-era-of-affordable-daas
#11
Rujipat Wasitthankasem, Preeyaporn Vichaiwattana, Chompoonut Auphimai, Nipaporn Siripon, Sirapa Klinfueng, Pisit Tangkijvanich, Sompong Vongpunsawad, Yong Poovorawan
The core antigen of the hepatitis C virus (HCV Ag) presents an alternative marker to HCV RNA when screening patients for HCV viremia. This study sought to evaluate the utility of HCV Ag as a marker to assess active HCV infection in individuals residing in an HCV-endemic area. From 298 HCV-seropositive individuals evaluated for the presence of anti-HCV antibody, HCV Ag and HCV RNA, anti-HCV antibody was detected in 252 individuals (signal-to-cutoff ratios ≥5), HCV RNA was detected in 222 individuals (88%), and HCV Ag was reactive (≥3 fmol/L) in 220 individuals (87%)...
2017: PeerJ
https://www.readbyqxmd.com/read/29132303/prevalence-of-naturally-occurring-ns5a-resistance-associated-substitutions-in-patients-infected-with-hepatitis-c-virus-subtype-1a-1b-and-3a-co-infected-or-not-with-hiv-in-brazil
#12
Fernanda Malta, Karine Vieira Gaspareto, Gaspar Lisboa-Neto, Flair José Carrilho, Maria Cássia Mendes-Correa, João Renato Rebello Pinho
BACKGROUND: Non-structural 5A protein (NS5A) resistance-associated substitutions (RASs) have been identified in patients infected with hepatitis C virus (HCV), even prior to exposure to direct-acting antiviral agents (DAAs). Selection for these variants occurs rapidly during treatment and, in some cases, leads to antiviral treatment failure. DAAs are currently the standard of care for hepatitis C treatment in many parts of the world. Nevertheless, in Brazil, the prevalence of pre-existing NS5A RASs is largely unknown...
November 13, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29125869/monitoring-the-treatment-of-hepatitis-c-with-directly-acting-antivirals-by-serological-and-molecular-methods
#13
Elisabetta Loggi, Silvia Galli, Giovanni Vitale, Roberto Di Donato, Ranka Vukotic, Elena Grandini, Marzia Margotti, Valeria Guarneri, Giuliano Furlini, Claudio Galli, Maria Carla Re, Pietro Andreone
AIM: To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs). METHODS: Ninety-six patients treated with DAAs, either alone (91) or in combination with PEG interferon (5), were tested for HCV-RNA and for HCV-Ag at baseline and at weeks 2, 4, 8 and 12 during treatment and 12 weeks after completion. The concordance and correlation between the viral parameters as well as the respective kinetics during and after treatment were evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/29121533/novel-treatments-for-chronic-hepatitis-c-closing-the-remaining-gaps
#14
REVIEW
Naim Alkhouri, Eric Lawitz, Fred Poordad
Direct acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection with cure rates >90% for the majority of patients and excellent safety profile. However, there remain certain unmet needs in treating HCV including treatment for patients that failed a prior DAA regimen and for those with advanced chronic kidney disease. In addition, shortening the duration of DAA regimens has the potential to increase compliance and decrease the cost of care. New regimens that were approved by the FDA in 2017 address these unmet needs and will be discussed in this concise review...
November 6, 2017: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29119934/direct-acting-antivirals-for-hiv-hcv-co-infected-individuals-as-good-as-it-gets
#15
Giuseppe Bruno, Annalisa Saracino
Although HIV/HCV co-infected individuals were historically considered a "difficult to treat" population in the era of Interferon (IFN)-based anti-HCV treatment, the introduction of direct-acting antivirals, characterized by excellent efficacy and good safety profile, has widely revolutionized the HCV treatment scenario. Recent real life studies reported excellent sustained virological response rates in HIV/HCV co-infected subjects, thus confirming data obtained in randomized clinical trials. However, certain issues have recently emerged in this population...
November 8, 2017: Current HIV Research
https://www.readbyqxmd.com/read/29119331/intestinal-amino-acid-and-peptide-transporters-in-broiler-are-modulated-by-dietary-amino-acids-and-protein
#16
Artyom Karlovich Osmanyan, Shahab Ghazi Harsini, Reza Mahdavi, Vladimir Ivanovich Fisinin, Anna Leonidovna Arkhipova, Tatiana Teodorovna Glazko, Svetlana Nikolaevna Kovalchuk, Gleb Yurievich Kosovsky
This study evaluated the effect of three levels of digestible amino acids (DAA; 100, 107 and 114% of Cobb recommendations) on mRNA abundance of peptide (PepT1) and amino acid (AA) transporters in 480-day-old broilers during prestarter period. Jejunal mRNA levels of the PepT1 and b(0,+)AT increased as DAA level increased from 100 to 114%. The expression of CAT1 mRNA in the jejunum was higher in birds fed 100% DAA diet. The transport systems B(0)AT and y(+)LAT1 were not affected by the dietary treatments. These results demonstrated that dietary content of protein and DAA differentially affected the expression of intestinal peptide and AA transporters to modulate absorption of peptide and AA in broilers...
November 8, 2017: Amino Acids
https://www.readbyqxmd.com/read/29116684/disparities-in-direct-acting-antivirals-uptake-in-hiv-hepatitis-c-co-infected-populations-in-canada
#17
Sahar Saeed, Erin C Strumpf, Erica Em Moodie, Jim Young, Roy Nitulescu, Joseph Cox, Alexander Wong, Sharon Walmsely, Curtis Cooper, Marie-Lousie Vachon, Valerie Martel-Laferriere, Mark Hull, Brian Conway, Marina B Klein
BACKGROUND: Direct acting antivirals (DAAs) have revolutionized hepatitis C (HCV) treatment with >90% cure rates even in real-world studies, giving hope that HCV can be eliminated. However, for DAAs to have a population-level impact on the burden of HCV disease, treatment uptake needs to be expanded. We investigated temporal trends in HCV treatment uptake and evaluated factors associated with second-generation DAA initiation and efficacy among key HIV-HCV co-infected populations in Canada...
November 2017: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/29116550/resistance-to-daas-when-to-look-and-when-it-matters
#18
REVIEW
David L Wyles
PURPOSE OF REVIEW: This review provides an overview of HCV resistance-associated substitutions (RASs) with a focus on NS3 protease and NS5A inhibitor resistance. Treatment approaches for managing resistance are also covered including the use of newly approved therapies with improved resistance profiles. RECENT FINDINGS: HCV RASs are frequently selected if the patient is not cured during treatment; NS5A RASs persist for prolonged periods of time (years) after treatment failure and may adversely impact retreatment responses...
December 2017: Current HIV/AIDS Reports
https://www.readbyqxmd.com/read/29115717/changes-in-liver-function-and-body-composition-by-direct-acting-antiviral-therapy-for-hepatitis-c-virus-infection
#19
Ryosuke Sugimoto, Motoh Iwasa, Nagisa Hara, Yasuyuki Tamai, Kyoko Yoshikawa, Suguru Ogura, Hideaki Tanaka, Akiko Eguchi, Norihiko Yamamoto, Yoshinao Kobayashi, Hiroshi Hasegawa, Yoshiyuki Takei
AIM: Management of low skeletal muscle mass (LSM) is a very important topic since LSM affects patient mortality in liver diseases. Changes in body composition are unexplored in chronic hepatitis C virus (HCV) patients, including those with liver cirrhosis, who receive direct-acting antiviral (DAA) therapy. Body composition measurements and liver function tests were performed before and after DAA therapy. METHODS: Blood examination, visceral fat area (VFA) and extremity skeletal muscle mass were measured using the multi-frequency bioelectrical impedance analysis method: i) at 24 weeks pre DAA therapy; ii) at the start of DAA therapy; iii) at the end of DAA therapy; iv) at 24 weeks post DAA therapy; and v) at 48 weeks post DAA therapy...
November 8, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29115151/sofosbuvir-velpatasvir-voxilaprevir-a-pan-genotypic-direct-acting-antiviral-combination-for-hepatitis-c
#20
Elias B Chahine, Denise Kelley, Lindsey M Childs-Kean
OBJECTIVES: To review the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C virus (HCV) infection. DATA SOURCES: A literature search through PubMed was conducted (August 2010 to August 2017) using the terms GS-9857, voxilaprevir, and NS3/4A protease inhibitor. STUDY SELECTION/DATA EXTRACTION: Studies of sofosbuvir/velpatasvir/voxilaprevir were identified. DATA SYNTHESIS: Sofosbuvir/velpatasvir/voxilaprevir is indicated for adult patients with chronic HCV without cirrhosis or with compensated cirrhosis who have (1) genotype 1 through 6 and have previously been treated with an NS5A inhibitor or (2) genotype 1a or 3 and have previously been treated with sofosbuvir without an NS5A inhibitor...
November 1, 2017: Annals of Pharmacotherapy
keyword
keyword
68491
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"